Journal
MOLECULAR PSYCHIATRY
Volume 17, Issue 1, Pages 22-35Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2011.121
Keywords
bipolar disorder; post-traumatic stress disorder; brain-derived neurotrophic factor
Funding
- K23 award [K23MH086690]
- AstraZeneca
- Novartis
- Evotec
- Forest
- GlaxoSmith-Kline
- Ono Pharmaceuticals
- Pfizer
- Takeda
- Wyeth
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025008] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH086690] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Bipolar disorder (BD) and post-traumatic stress disorder (PTSD) frequently co-occur among psychiatric patients, leading to increased morbidity and mortality. Brain-derived neurotrophic factor (BDNF) function is associated with core characteristics of both BD and PTSD. We propose a neurobiological model that underscores the role of reduced BDNF function resulting from several contributing sources, including the met variant of the BDNF val66met (rs6265) single-nucleotide polymorphism, trauma-induced epigenetic regulation and current stress, as a contributor to the onset of both illnesses within the same person. Further studies are needed to evaluate the genetic association between the val66met allele and the BD-PTSD population, along with central/peripheral BDNF levels and epigenetic patterns of BDNF gene regulation within these patients. Molecular Psychiatry (2012) 17, 22-35; doi:10.1038/mp.2011.121; published online 20 September 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available